Skip to main content
. Author manuscript; available in PMC: 2021 Sep 8.
Published in final edited form as: Circulation. 2020 Jul 2;142(10):948–962. doi: 10.1161/CIRCULATIONAHA.119.044893

Figure 3. A polyproline domain-anchoring disruptor inhibits adult rat ventricular myocyte hypertrophy in vitro.

Figure 3.

A-D. Myocytes were infected with adenovirus expressing CaNAα, CaNAβ2, or control shRNA and then stimulated for 24 hours with 20 μmol/L phenylephrine (PE) before immunocytochemistry using α-actinin antibodies (red) and Hoechst nuclear stain (blue). A. Representative myocyte images. Scale bar − 10 μm. B-D. Bars and symbols indicate average mean and means of independent experiments using different myocyte preparations, respectively, for width (Cf. Figure IVA in Data Supplement), length, and width/length ratio. n = 4 independent experiments. *p-value vs. no drug control for the same shRNA. †vs. control shRNA under the same treatment condition; ‡vs. CaNAα shRNA under same the treatment condition. E-H. Myocytes were infected with adenovirus expressing GFP, β-Gal, or a CaNAβ PP-GFP fusion protein and then stimulated for 24 hours with 20 μmol/L PE or 10 μmol/L isoproterenol (Iso). E. Representative myocyte images stained as in A. Scale bar − 10 μm. F-H. Bars and symbols indicate average mean and means of independent experiments using different myocyte preparations, respectively, for width (Cf. Figure IVF in Data Supplement ), length, and width/length ratio. n = 4 independent experiments. *p-value vs. no drug control for the same protein. †vs. GFP under the same treatment condition; ‡vs. β-gal under the same treatment condition. All data were analyzed by 2-way ANOVA for matched data with Tukey post-hoc testing. Repeated symbols are used as follows: single - p ≤ 0.05; double - p ≤ 0.01; triple - p ≤ 0.001.